Imperial Tobacco Group PLC (ITYBY: OTCQX International

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Imperial Tobacco Group PLC (ITYBY: OTCQX International Premier) | Intention to float Logista

NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR CANADA, JAPAN OR IN ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

10 June 2014

Imperial Tobacco Group PLC - Logista

Imperial Tobacco Group PLC (?Imperial Tobacco?) announces intention to float Compa??a de Distribuci?n Integral Logista Holdings, S.A. (?Logista?)

On 13 February 2014 Imperial Tobacco responded to speculation about Logista and confirmed it was reviewing its options in relation to a potential IPO of Logista.

Following that review, Imperial Tobacco today announces its intention to launch an IPO of Logista involving its indirectly wholly-owned subsidiary Altadis S.A.U. to sell a portion of its shares to institutional investors. Imperial Tobacco intends to retain the majority of Logista shares.

Logista, the leading integrated tobacco distribution and logistics company in Southern Europe, is intended to list on the Spanish Stock Exchanges. Read a separate release from Logista at http://www.grupologista.com/en/inversores/

 

Contacts:

Tom Corran

Director of Investor Communication

Imperial Tobacco Group PLC

0117 933 7510

 

Simon Evans
Group Press Officer
Imperial Tobacco Group PLC

+44 (0)7967 467684

 

 

Legal Disclaimer

These materials are not for release, distribution or publication, whether directly or indirectly and whether in whole or in part, into or in the United States, Canada or Japan or any (other) jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

These materials are for information purposes only and are not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy any securities of Compa??a de Distribuci?n Integral Logista Holdings, S.A.U. (the Company, and such securities, the Securities) in the United States, Canada or Japan or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction.

The Securities are not and will not be registered under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act) and will also not be registered with any authority competent with respect to securities in any state or other jurisdiction of the United States of America. The Securities may not be offered or sold in the United States of America absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act. There will be no public offering of Securities in the United States.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, ?qualified investors? (as

defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of ?investment professionals? in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ?Order?); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ?relevant persons?). Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

In Australia this document is for distribution only to professional or sophisticated investors (i.e. those persons to whom offers can be made without a disclosure document, in accordance with sections 708(8) and (11) of the Corporations Act 2001 (Cth)) who are ?wholesale clients? within the meaning of section 761G of the Corporations Act 2001 (Cth). The entity receiving this document represents and warrants that if it is in Australia it is a wholesale client and either a professional or sophisticated investor and that it will not distribute this report to any person outside Australia. This document is not supplied in connection with any offering of securities in the Company. A decision whether to subscribe for the Company?s securities should be made on the basis of the information in the disclosure document which will be issued by the Company.

The Company has not authorised any offer to the public of Securities in any Member State of the European Economic Area.

This communication is an advertisement for the purposes of Article 15 of Prospectus Directive 2003/71/EC and Article 28 of Spanish Royal Decree 1310/2005 of 4 November (Real Decreto 1310/2005 de 4 de noviembre). Investors should not purchase (or subscribe for) any shares referred to in this announcement except on the basis of information in the prospectus to be published by the Company in due course in connection with the Offering and the admission of the shares in the capital of the Company on the Spanish Stock Exchanges.

As of the date of this communication, a draft prospectus relating to the Offering is pending approval by the Spanish National Securities Market Commission (Comisi?n Nacional del Mercado de Valores). Once approved, the prospectus will be made available to investors.

With respect to any Member State of the European Economic Area, and which has implemented the Prospectus Directive (each a Relevant Member State), no action has been undertaken or will be undertaken to make an offer to the public of Securities requiring publication of a prospectus in any Relevant Member State. As a result, the Securities may only be offered in Relevant Member States (i) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (ii) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purpose of this paragraph, the expression "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the Securities to be offered so as to enable the investor to decide to exercise, purchase or subscribe for the securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State.

No action has been taken by the Company that would permit an offer of Securities or the possession or distribution of these materials or any other offering or publicity material relating to such Securities in any jurisdiction where action for that purpose is required.

The release, publication or distribution of these materials in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which they are released, published or distributed, should inform themselves about, and observe, such restrictions.

An offer to acquire Securities pursuant to the proposed offering will be made, and any investor should make his investment, solely on the basis of information that will be contained in the prospectus to be made generally available in Spain in connection with such offering. When made generally available, copies of the prospectus may be obtained at no cost from the Company or through the website of the Company.

Credit Suisse and Goldman Sachs International act exclusively for the Company and no-one else in connection with any offering of the Securities and will not be responsible to anyone other than the Company for providing the protections afforded to the customers of Credit Suisse and Goldman Sachs International or for providing advice in relation to any offering or any transaction or arrangement referred to herein.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading